Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer. [PDF]
Samudrala R +3 more
europepmc +1 more source
Use of tandem-affinity chromatography to incorporate nucleotide loading of small GTPases during their purification. [PDF]
Oladimeji R +4 more
europepmc +1 more source
KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers. [PDF]
Yan M +5 more
europepmc +1 more source
Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways. [PDF]
Garg V +11 more
europepmc +1 more source
SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics. [PDF]
Eom J, Chun Y, Chang HR.
europepmc +1 more source
KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We Have All Been Waiting for. [PDF]
Stanger BZ, Vonderheide RH.
europepmc +1 more source
C-MYC as a key effector of WNT, PI3K/AKT, MAPK, and TGF-β signaling pathways in regulation of epithelial-mesenchymal transition during tumor metastasis. [PDF]
Moghbeli M.
europepmc +1 more source
KRAS Footprints in the Skin: Leveraging Targeted Therapy for Unresectable Intra-Cerebral AVM. [PDF]
Zhang D +5 more
europepmc +1 more source
RASGRP4 is a key factor in the KRAS activation mediated by SOS in tumor Y1 adrenocortical cell lines. [PDF]
Montoni F +6 more
europepmc +1 more source
Targeting MET and KRAS G12C co-occurring mutation in metastatic adenoid cystic carcinoma of the trachea: a case report. [PDF]
Zhang L, Wang T, Xu Y, Ji Y, Nie K.
europepmc +1 more source

